Churchill Capital Corp XII 3Q 2026: Net income $3.52M — 10-Q Summary

Churchill Capital Corp XII reported a net income of $3.52M for the quarter, driven by interest on trust-account investments. The company has not yet commenced operations or generated revenue. As of September 30, 2026, it had not entered into a definitive agreement for a business combination. The trust account held $419.4M in marketable securities and cash, with $1M withdrawn for working capital.

Original reporting
Published Nov 13, 2026, 9:21 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 9:29 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Churchill Capital Corp XII 3Q 2026: Net income $3.52M — 10-Q Summary — source image
Decision brief

The 30-second read

$CXIINeutralLow
01

Why it matters

The modest earnings provide a small positive data point but are unlikely to drive significant price movement given the SPAC's early stage and lack of operating revenue.

02

Market read

Limited to investors tracking SPAC filings; broader market impact is negligible.

03

What to watch

The $1M working‑capital draw could signal upcoming merger activity, which may be undervalued by the market.

Relevance 5/10Novelty 4/10Timing: post‑market filing today

Background

Churchill Capital Corp XII (CXII) is a SPAC that has not yet completed a business combination. The filing reports its first quarterly net income and trust‑account activity.

Company-level read

Ticker impact

$CXIINeutralMedium confidence
Context

The 10‑Q disclosed net income of $3.52M and a $1M trust‑account withdrawal, the first public filing of these figures for the SPAC.

Expected impact

likely modest upward pressure as investors note positive net income but scale is small

Evidence & confidence

Micro‑cap SPACs with modest earnings rarely move sharply; the disclosed profit is modest relative to the $419M trust balance.

Market effects

Minimal effect on the broader SPAC or blank‑check vehicle sector.

No discernible regional impact.

Limited relevance outside niche SPAC investors.

Counterpoint

Investors may view the profit as a sign of underlying asset value and bid the SPAC higher despite its early stage.

Key entities

  • Churchill Capital Corp XII

    SPAC awaiting a merger target

Related articles

$SBCHigh

Why SBC Medical Stock Skyrocketed on Friday

SBC Medical Group (NASDAQ:SBC) shares rose 37% after reporting Q3 revenue of $59M, up 35% YoY, and announcing an AI partnership with NeuroBrain Dynamics. The company added 36 clinics, increasing total locations to 293, and saw a 9% rise in patient visits. Operating income surged 66% to $26M, with a 45% operating margin.

$BTOMedAI 8/10

B2Gold Earnings Call Signals Lower Costs and Growth

B2Gold Corp. reported Q3 earnings with strong production, lower cost guidance, and positive free cash flow. The company produced 193,000 ounces of gold, reduced all-in sustaining cost guidance by over $100 per ounce, and generated $48 million in free cash flow. Revenue reached $836 million, supported by higher gold prices. The company also highlighted growth projects and shareholder returns.

$NMAXMed

Why Newsmax Stock Popped on Friday

Newsmax (NMAX) shares rose 31% after reporting Q3 revenue of $69M, up 52.5% YoY, and net income of $15.2M. The company cited strong audience engagement and growth in high-margin revenue streams. CEO Christopher Ruddy expects continued growth ahead of the presidential election.

$LUNRMed

What Is Driving Intuitive Machines Stock?

Intuitive Machines (LUNR) shares rose 7.0% on Nov 12, 2026, after reporting Q3 revenue of $269M, beating estimates. The company's loss of $0.10 per share met expectations, while gross margin improved to 26%. Free cash flow turned positive at $33M, a company record. Management raised full-year revenue guidance to $920M-$950M. The stock's performance contrasted with broader industry declines.

$RMIXMedAI 8/10

Suncrete (RMIX) Q3 2026 Earnings Call Transcript

Suncrete (RMIX) reported Q3 2026 revenue of $141M, up 45% QoQ and 163% YoY. Adjusted EBITDA rose 66% QoQ to $22.4M. The company lowered its full-year outlook due to residential construction weakness but remains confident in long-term demand. Acquisition integration is progressing, with North Texas showing margin improvement. Suncrete expects $200M-$250M revenue from 2026 acquisitions in 2027. The company has $206.5M in total liquidity.

$CLLSMed

Cellectis SA (CLLS) (Q3 2026) Earnings Call Highlights: Strategic Shift to Gene

Cellectis SA (CLLS) discussed its strategic shift to gene editing during its Q3 2026 earnings call. Management highlighted the selection of APOC3 over ANGPTL3 for triglyceride reduction, with plans to start Phase 1 dosing by end-2027. The company reported $149M in cash as of September 30, 2026, with a runway into H2 2028. Revenue decreased to $19.9M from $67.4M YoY, while R&D expenses increased to $108.8M from $69.1M, driven by the AstraZeneca collaboration.